Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4619 - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Breast Cancer

Presenters

Joanna Huszno

Citation

Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268

Authors

J. Huszno1, Z. Kolosza2, J. Mrochem-Kwarciak3, A. Zajusz4

Author affiliations

  • 1 Genetic Outpatient Clinic, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
  • 2 Biostatistic Unit, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, 44-101 - Gliwice/PL
  • 3 Analytics And Clinical Biochemistry Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, 44-101 - Gliwice/PL
  • 4 Genetic Outpatient Clinic, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, 44-101 - Gliwice/PL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4619

Background

Inflammation impacts each step of tumorigenesis, including tumor initiation, promotion and metastatic progression. Biomarkers including the neutrophil, lymphocyte and platelet count, as well as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) are indices of inflammation. The aim of the present study was to assess the blood the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) as a prognostic factors in male breast cancer patients (BC).

Methods

A the retrospective analysis of 38 male BC patients who were treated at COI (Gliwice, Poland) between January 2005 and December 2018 was performed. Based on the cut-off values determined, the NLR was considered as ‘elevated’ at > 2.65, the MLR value was ‘elevated’ at > 0.28 and the PLR was considered ‘elevated’ at > 190.9. The prognostic value (OS) of the pre-treatment PLR, NLR and MLR was assessed by univariate analysis.

Results

There was observed tendency to worse 5-year OS in male BC patients with lymph node metastases (N+) (43.5% vs. 73.9%, p = 0.171); higher tumor size (T4 vs. T1) (42% vs.85.79%, p = 0.128); negative steroid receptor status (PR-) (28.6% vs. 65.6%, p = 0.109). Patients with cancer family history had significantly better 5-year OS than patients without cancer family history (86.3% vs.35.0%, p = 0.004).Younger male BC patients (age ≤53 years) had better 5 year OS in comparison to patients over 53 years (88.9% vs. 43.1%, p = 0.014).The 5-year OS was lower in patients with lower lymphocyte value ≤1.52 (24.0% vs. 67.4%, p = 0.010). There was reported tendency to the worse 5-year OS in patients with higher PLT value (PLT>193 x 10^3) (47.3% vs. 78.8%, p = 0.157). The 5-year OS was lower in the NLR >2.75 compared with that in the NLR≤2.75 group (29.6% vs. 64.4%, p = 0.031). Similarly, a worse OS rate was associated with an elevated PLR (>114.5) (34.4% vs.77.5%, p = 0.021). There was detected tendency to worse OS in group with lower MLR level (≤3.23) (39.5% vs. 71.9%, p = 0.155).

Conclusions

The present results revealed that an elevated NLR (>2.75) and PLR (>114.5) are associated with poor OS in male breast cancer patients. In contrary, the elevated MLR affected better OS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.